An Open Trial to Evaluate the Efficacy and Side Effects of Vigabatrin Add-on Therapy in Pharmacoresistant Patients with Partial Epilepy

• Main Authors: Chung, Huan, 鍾渙
• Other Authors: Tsai.Jing-Jane, Kao.Yea-Huei
• Format: Others
• Language: zh-TW
• Published: 1998
• Online Access: http://ndltd.ncl.edu.tw/handle/82878531280839114207

碩士 === 國立成功大學 === 臨床藥學研究所 === 86 === Objective: To evaluate the efficacy and side effects of vigab patients with pharmacoresistant partial epilepsy.Patients: Patients with pharmacoresistant partial epilepsy treated at epileptic clinic of National Cheng Kung University Hospital regularly who were above 18 years old with at least once seizure attack every four weeks for 12 weeks were recruited. Those who had the history of psychosis, progressive neurological disorders, known poor compliance and women planing to be pregant were excluded. Methods: The baseline period lasted for 12 weeks when the AED regimen remained constant. During the escalation phase, 500 mg VGB was given daily in the first week and with an increment of 500 mg every week up to 3g daily. Maintenance phase at the daily dose of 3 gm continued for at least 12 week. the patients visited epilepsy clinic every 4 weeks and presented the seizure diary in which seizure type, seizure frequency and any adverse event should be recorded. the change of seizure frequency from baseline to maintenance phase wiil be calculated and tested by t test and nonparametric test.Result: Forty-seven patients jointed the study. One patient was withdrawn because of psychosis during the study and one patient loss follow. Consequently, 45 patients finished the maintenance phase of 12 weeks and 37 of them continued maintenance phase treatment phase of 12 weeks and 37 of them continued maintenance phase treatment to 24 weeks. In the maintenance phase of 12 week, the mean seizure frequency reduction rate is 49%. 24 (53.4) out of patients obtained more than 50% reduction of seizure at of the study and 3 of them were free during this period. In the maintenance phase of 24 weeks, 15 patients obtained reduction of seizure frequency more than 50%, and 4 of them were seizure free. The mean seizure frequency reduction rate was 36.9%. Drowsiness was the most common adverse effect reported. Only 2 patients withdrawn from the study due to adverse effects. Conclusion: This study showed VGB is effective and well tolerated in the add-on therapy for 12 and 24 weeks among persons with drug resistant partial epilepsy.